文献速递放疗物理与技术姑息放疗与转移瘤

无症状癌症队列中SARS-CoV-2患病率:结果与临床常规应对

SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine.
PubMed 文献 · Radiat Oncol · 2020-07-09

德国一家大型放射治疗科实施大流行适配的卫生防护措施,并对139例无症状癌症患者在新定位CT前进行鼻咽拭子PCR检测。仅1例阳性,患病率0.72%,无工作人员阳性,阳性患者治疗推迟2周。作者认为初始筛查有助于识别无症状感染者,但常规每周两次检测受检测能力限制。

要点

  • 139例无症状癌症患者中仅1例SARS-CoV-2 PCR阳性,患病率0.72%。
  • 截止报告时无工作人员检测阳性,阳性患者放疗推迟2周开始。
  • 作者认为初始筛查可保护其他患者和员工,但常规高频检测受检测能力限制。

核心结论

  • 大流行适配措施下放疗科似准备充分,初始PCR筛查有助于识别无症状COVID-19患者以保护其他患者和员工。
  • 观察到的PCR患病率与同类研究一致,常规每周两次检测所有患者和员工原则上可取但当前受检测能力限制。

研究设计与样本

  • 单中心前瞻性实施报告,来自德国一家大型放射治疗科,对无症状癌症患者进行SARS-CoV-2 PCR筛查。
  • 实施大流行适配的卫生条例与预防措施后,对所有新无症状患者在模拟CT前不久于筛查站行鼻咽拭子PCR检测。

主要发现

  • 139例无症状癌症患者中仅1例SARS-CoV-2 PCR阳性,该癌症人群患病率为0.72%。
  • 截止报告时无工作人员检测阳性。
  • PCR阳性患者的治疗开始推迟2周。
  • 所有措施和实施通过患者与员工接受度半定量评估,接受良好。

关键数值与推荐

  • 两病区自开始时实施探视禁令,医务人员和患者须始终佩戴面罩。
  • 候诊室重新布置以确保患者间至少1.5米距离。
  • 临床随访主要经电话进行,所有患者进入科室前须完成症状和COVID-19患者接触史问卷。
  • 为新无症状患者在模拟CT前不久行鼻咽拭子PCR检测。

临床怎么用

  • 放疗科可实施探视禁令、普遍口罩、候诊距离、电话随访和症状/接触问卷等大流行适配措施。
  • 对新无症状癌症患者在模拟CT前进行鼻咽拭子PCR筛查,有助于识别无症状感染者并保护其他患者和员工。
  • PCR阳性患者可推迟治疗开始以降低传播风险,本报告中推迟2周。

局限性

  • 常规PCR检测(如每周两次)所有患者和员工原则上可取,但当前受检测能力限制。
  • 措施接受度为半定量评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Starting in December 2019, the current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confronts the world with an unprecedented challenge. With no vaccine or drug being currently available to control the pandemic spread, prevention and PCR (Polymerase chain reaction) testing becomes a crucial pillar of medical systems. Aim of the present study was to report on the first results of the measures taken in a large German Department of Radiation Oncology, including PCR testing of asymptomatic cancer patients. METHODS: Pandemic-adapted hygiene regulations and prevention measures for patients and staff were implemented. A visiting ban on both wards was implemented from the beginning and medical staff and patients were required to wear face masks at all times. The waiting rooms were rearranged to ensure distance between patients of at least 1.5 m. Clinical follow up was mainly done by telephone and all patients had to complete a questionnaire regarding symptoms and contacts with COVID-19 patients before entering our department. Educational documents were created for patients to raise awareness of symptoms and avoidance strategies for interactions with other people. Indications for therapy and fractionation schemes were adapted when possible. In a subsequent step, all new asymptomatic patients were tested via nasopharyngeal swab at our screening station shortly before their simulation CT. RESULTS: All these measures and implementations have been well accepted semiquantitatively measured by the consent received from patients and staff. Regarding the PCR testing, only 1 out of 139 asymptomatic patients of our cohort so far tested positive for SARS-CoV-2, reflecting a prevalence of 0.72% in this cancer patient population. Up to this point no staff members was tested positive. The start of the treatment for the PCR-positive patient was deferred for 2 weeks. CONCLUSION: Due to the pandemic-adapted implementations, our department seems well prepared during this crisis. The initial screening helps to identify asymptomatic COVID-19 patients in order to protect other patients and our staff from infection and the observed PCR prevalence is in line with comparable studies. A regular PCR testing (e.g. twice a week) of all patients and staff would in principle be desirable but is limited due to testing capacities at present.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Marschner S, Corradini S, Rauch J, et al. SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine. Radiat Oncol. 2020. PMID: 32646505. doi:10.1186/s13014-020-01609-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。